Claude Sonnet 5 chose a gene therapy and operated on a mouse brain without human decisions
AIExin Therapeutics CEO Gabriel Ocana-Santero says a Claude Sonnet 5 agent selected a drug, brain target and coordinates, then performed an injection in an epilepsy mouse model. The agent refused to continue when its target fell outside the device's range of motion, and Ocana-Santero fixed the code by hand.
AIWhy it matters.
The article shows how an agent's refusal during a live procedure exposed the tension between autonomy and safety guardrails in lab automation.
Source details
The Decoder · Matthias Bastian · the-decoder.comPublished · added here
Original title: A Claude model autonomously chose a gene therapy and operated on a mouse brain with no human decision-making